{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:46:34Z","timestamp":1790934394411,"version":"4.1.0"},"reference-count":46,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      This study aimed to estimate the cost-effectiveness of treating invasive aspergillosis (IA) in patients with limited treatment options with either olorofim or currently available antifungal salvage therapy from a US payer perspective. A hybrid decision tree-Markov model with a one-year time horizon was used to estimate health economic outcomes. The model considered probabilities of treatment response, mortality, and treatment-emergent adverse events; costs of antifungals and healthcare utilization; and patient utility. For olorofim, patient-level data from the open-label, single-arm, Phase IIb study of olorofim for the treatment of proven or probable IA with limited treatment options (Study 32,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03583164\" xlink:type=\"simple\">NCT03583164<\/jats:ext-link>\n                      ) was used. Salvage therapy data were based on an external control arm of a study of IA patients. A willingness-to-pay threshold of $50,000\/quality-adjusted life-year (QALY) was assumed to assess the cost-effectiveness of olorofim versus salvage therapy. One-year costs (2023 USD) of treating IA in patients with limited alternative options were $208,696 for currently available salvage therapy and $167,971 for olorofim, for an incremental cost reduction of $40,725. QALYs were 0.46 for olorofim and 0.22 for salvage therapy. Olorofim was determined to be a dominant (less costly, more effective) strategy, with an incremental net monetary benefit of $52,827. Olorofim remained the dominant strategy across all sensitivity analyses. Upon probabilistic sensitivity analysis, olorofim was dominant in 90.0% of 1,000 iterations and cost-effective in 97.5%. Olorofim resulted in lower total treatment costs, antifungal costs, and more QALY gains versus currently available salvage therapy, making olorofim the dominant strategy for treating IA with limited treatment options.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.00570-25","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T14:08:55Z","timestamp":1756303735000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness of olorofim in the treatment of invasive aspergillosis in patients with limited suitable alternative treatment options: a US payer perspective"],"prefix":"10.1128","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4142-8711","authenticated-orcid":true,"given":"Thomas J.","family":"Walsh","sequence":"first","affiliation":[{"name":"Center for Innovative Therapeutics and Diagnostics","place":["Richmond, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4868-7158","authenticated-orcid":false,"given":"Craig I.","family":"Coleman","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02der9h97","id-type":"ROR","asserted-by":"publisher"}],"name":"School of Pharmacy, University of Connecticut","place":["Storrs, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Blissett","sequence":"additional","affiliation":[{"name":"Maple Health Group","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Prawitz","sequence":"additional","affiliation":[{"name":"Maple Health Group","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bonetti","sequence":"additional","affiliation":[{"name":"Maple Health Group","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Aguiar","sequence":"additional","affiliation":[{"name":"Maple Health Group","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bresnik","sequence":"additional","affiliation":[{"name":"F2G Inc","place":["Princeton, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9986-2326","authenticated-orcid":true,"given":"Belinda","family":"Lovelace","sequence":"additional","affiliation":[{"name":"F2G Inc","place":["Princeton, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof6030122"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy181"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1309\/UJRV9DLC11RM3G8R"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2017.1283986"},{"key":"e_1_3_1_6_2","unstructured":"World Health Organization. 2022. WHO fungal priority pathogens list to guide research development and public health action. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240060241"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw326"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.152900"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00219-1"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2106.140717"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-023-00960-9"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2015.08.001"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku566"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01611-0"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae103"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00224-5"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-067975"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/588660"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.01.002"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/508774"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm196"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020191"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-013-0123-9"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079905x65312"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S44947"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000001227"},{"key":"e_1_3_1_28_2","unstructured":"RED BOOK Online. 2023. IBM Micromedex [database online]. Truven Health Analytics Greenwood Village CO. Available from: https:\/\/www.micromedexsolutions.com"},{"key":"e_1_3_1_29_2","unstructured":"Centers for Medicare & Medicaid Services. 2023. Physician Fee Schedule. Available from: https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search"},{"key":"e_1_3_1_30_2","unstructured":"Agency for Healthcare Research and Quality. 2024. Healthcare Cost and Utilization Project (HCUPnet). Available from: https:\/\/datatools.ahrq.gov\/hcupnet"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.02.009"},{"key":"e_1_3_1_32_2","unstructured":"US Food and Drug Administration. 2013. Orphan Drug Act-Relevant Excerpts. Available from: https:\/\/www.fda.gov\/industry\/designating-orphan-product-drugs-and-biological-products\/orphan-drug-act-relevant-excerpts"},{"key":"e_1_3_1_33_2","unstructured":"Institute for Clinical and Economic Review (ICER). 2019. Perspectives on cost-effectiveness threshold ranges. Available from: https:\/\/icer.org\/wp-content\/uploads\/2023\/08\/ICER_2019_Perspectives-on-Cost-Effectiveness-Threshold-Ranges.pdf"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.516110"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab163"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2025.01.002"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1086\/652768"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01159-9"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.7326\/M13-2508"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1086\/423381"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz258"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy859"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-014-0722-7"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.3109\/13693786.2012.690108"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx423"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2014.07.007"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12454941"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00570-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00570-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:03:10Z","timestamp":1759323790000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00570-25"}},"subtitle":[],"editor":[{"given":"Damian J.","family":"Krysan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1128\/aac.00570-25"],"URL":"https:\/\/doi.org\/10.1128\/aac.00570-25","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00570-25"}}